机构：[1]Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.[2]Oncology Department, Leshan People’s Hospital, Sichuan, 614000, China.
The combination of dendritic cells (DCs) and cytokine-induced killer cells (CIKs) can induce the anti-tumor immune response and radiotherapy may promote the activity. We aimed to explore the feasibility of DCs/CIKs combined with thoracic radiotherapy (TRT) for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).
In this study, patients with unresectable stage III/IV NSCLC and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2 and previously receiving two or more cycles of platinum-based doublet chemotherapy without disease progression received TRT plus DCs/CIKs or TRT alone until disease progression or unacceptable toxicity. The primary endpoint was median progression-free survival (mPFS). In treatment group, patients received four-cycle autologous DCs/CIKs infusion starting from the 6(th) fraction of irradiation.
From Jan 13, 2012 to June 30, 2014, 82 patients were enrolled, with 21 patients in treatment group and 61 in control group. The mPFS in treatment group was longer than that in control group (330 days vs 233 days, hazard ratio 0.51, 95 % CI 0.27-1.0, P < 0.05), and the objective response rate (ORR) of treatment group (47.6 %) was significantly higher that of control group (24.6 %, P < 0.05). There was no significant difference in disease control rate (DCR) and median overall survival (mOS) between two groups (P > 0.05). The side effects in treatment group were mild and there was no treatment-related deaths.
The combination of DCs/CIKs with TRT could be a feasible regimen in treating locally advanced or metastatic NSCLC patients. Further investigation of the regimen is warranted.
基金：
National Natural Science Foundation of China
(No. 81272496), Chongqing Natural Science Foundation (No. cstc2012jjB10003,
cstc2012jjA10096), Clinical Research Fund of Third Military Medical University
(No. 2011XLC38).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类|3 区医学
小类|3 区核医学4 区肿瘤学
最新[2025]版：
大类|2 区医学
小类|2 区核医学3 区肿瘤学
第一作者：
第一作者机构：[1]Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Luping,Xu Yanmei,Shen Jie,et al.Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.[J].Radiation oncology (London, England).2016,11:60.doi:10.1186/s13014-016-0635-5.
APA：
Zhang Luping,Xu Yanmei,Shen Jie,He Feng,Zhang Dan...&Sun Jianguo.(2016).Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer..Radiation oncology (London, England),11,
MLA：
Zhang Luping,et al."Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.".Radiation oncology (London, England) 11.(2016):60
